Capecitabine-warfarin interaction

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1546-1551

  Janney, Laurel M ^a   Waterbury, Nancee V ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Capecitabine; Colon cancer; Warfarin

Indexed keywords

ATROPINE; CAPECITABINE; CYTOCHROME P450 2C9; DIPHENOXYLATE; FLUOROURACIL; FOLINIC ACID; HYDROMORPHONE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; POTASSIUM CHLORIDE; PROCHLORPERAZINE; RABEPRAZOLE; RECOMBINANT ERYTHROPOIETIN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CAPILLARY RESISTANCE; CASE REPORT; COLON CANCER; HUMAN; MALE; METASTASIS; MITRAL VALVE REPLACEMENT; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DRUG INTERACTIONS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MITRAL VALVE; WARFARIN;

EID: 23944472628     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G153     Document Type: Article

References (9)

1. Package insert. Xeloda (capecitabine). Nutley, NJ: Roche Pharmaceuticals, April 2003.
2. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999;35:1338-42.
3. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-87.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
5. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104.
6. FDA Center for Drug Evaluation and Research. Clinical pharmacology/biopharmaceutics review. www.fda.gov/cder/foi/nda/2001/20- 896S10S11_Xeloda.htm (accessed 2005 Jan 31).
7. FDA Center for Drug Evaluation and Research. Administrative documents. Post-marketing safety review. www.fda.gov/cder/foi/nda/2001/ 20-896S10S11_Xeloda.htm (accessed 2005 Jan 31).
8. Copur MS, Ledakis P, Bolton M, Morse AK, Werner T, Norvell M, et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin Colorectal Cancer 2001;1:182-4.
9. Buyck HCE, Buckley N, Leslie MD, Plowman PN. Capecitabine-induced potentiation of warfarin (letter). Clin Oncol 2003;15:297.